HCS Pharma, expert in cellular imaging & in vitro assay development for High Content Screening (HCS) & Analysis (HCA) has just acquired BIOMIMESYS® Technology, a biomimetic hydrogel scaffold based on biofunctionalized hyaluronic acid with extracellular matrix components for 3D cell culture.
If you have already used BIOMIMESYS® products, be aware that they will be available again in early 2018! If you do not know yet this technology, please let us know your interest.
Using BIOMIMESYS® Technology, HCS Pharma will also provide its expertise in HCS/HCA to evaluate the efficacy, mode of action, and safety of your therapeutic molecules on 3D cell models.
Ask us for a TC to know more about our services and products.
BIOMIMESYS® Plates’ assets:
- Natural biofunctionnalized scaffold
- Ready-to-use and easy to handle for highly reproducible experiments
- Compatible with HTS & HCS
- Use also for long term cultures & in vivo transplantation
- Ease of cell retrieval, PCR & WB analysis
3D-printed minifactories at ETH Zurich | HCS-pharma · December 21, 2017 at 3:20 pm
[…] In HCS Pharma we are very interested by this evolution and we are working on our biomimetic hydrogel… […]